Although multiple antihypertensive agents are required to control blood pressure (BP) in chronic renal disease, it remains undetermined whether the combination therapy with angiotensin receptor blockers (ARB) plus calcium antagonists or angiotensin-converting enzyme inhibitors (ACEI) confers more preferable action on renal disease than the ARB monotherapy. In the present study, we compared the effect of the combination therapy with ARB plus calcium antagonists/ACEI on proteinuria with that of the ARB monotherapy in chronic nondiabetic renal disease. At 1 month of the drug treatment, the candesartan monotherapy (n ¼ 19) reduced BP from 15473/9372 to 14673/8872 mmHg (Po0.05), and a similar magnitude of BP reductions was observed with the combination therapy with candesartan plus ACEI/amlodipine (from 15372/9572 to 14472/8872 mmHg, Po0.05, n ¼ 39). The depressor action of these therapies was sustained throughout the 12-month treatment. In contrast, the reduction in proteinuria was greater with the combination therapy (À5273% at 12 months, n ¼ 39) than with the candesartan monotherapy (À2573%, n ¼ 19), although the baseline values of proteinuria were nearly the same in the candesartan monotherapy group (1.7470.22 g/day) and the combination therapy group (2.1070.19 g/day, P40.2). Of note, the proteinuria-sparing effect did not differ between the candesartan þ ACEI group and the candesartan þ amlodipine group. In conclusion, the present study suggests more beneficial action of the combination therapy with ARB plus ACEI/amlodipine than the ARB monotherapy in nondiabetic renal disease. Since the reduction in BP was achieved to the same level, the distinct proteinuria-sparing action of these therapies is attributed to BP-independent mechanisms, which should vary depending on the agents used.
Introduction
Hypertension causes pressure-induced damage of multiple organs. Renal injury is of particular importance since its presence is associated with increased cardiovascular events. 1 Furthermore, it has been demonstrated that proteinuria per se elicits renal interstitial injury, 2 and the degree of proteinuria is correlated with the rate of progression of renal disease, 3 thus forming a vicious circle to the development of end-stage renal disease. Since the improvement in proteinuria is achieved by reducing systemic blood pressure (BP) 4, 5 or dilating renal efferent arterioles, 6, 7 both of which decrease glomerular capillary pressure, the strategy to induce these changes with antihypertensive agents including calcium antagonists, ACE inhibitors and angiotensin receptor blockers (ARB) teleologically should contribute to a decrease in cardiovascular events.
Despite the substantial progress of pharmaceutical strategy, it appears extremely difficult to halt the progression of renal disease. It is well accepted that the beneficial action of antihypertensive agents becomes greater when the systemic BP reaches the lower BP level, and indeed the optimal target BP for renal disease is set at lower BP than that for uncompromised hypertension. 5, 8 Thus, the combination therapy of antihypertensive agents is usually required to obtain target BP levels and subsequently to prevent the deterioration of renal dysfunction in renal disease, 9 and calcium antagonists are widely used as a counterpart of ACE inhibitors or ARB because of their effectiveness and less adverse effects. Furthermore, dual blockade of renin-angiotensin system with ACE inhibitors and ARB has recently attracted much attention, and several lines of study suggest a more beneficial action of this therapeutic strategy than that of each agent alone in renal disease. 10, 11 Nevertheless, it has not been fully evaluated whether the combination therapy with ARB and calcium antagonists/ACE inhibitors is more beneficial than the ARB monotherapy when BP reaches the same level.
In the present study, we examined the effect of a 12-month treatment with the candesartan cilexetil (CDS) monotherapy or the combination therapy with CDS plus amlodipine or ACE inhibitors on systemic BP and proteinuria in patients with nondiabetic renal disease, and compared the proteinuria-sparing effect of these treatment strategies in renal disease.
Methods

Patient profiles
In all, 58 outpatients (27-76 years old) with hypertension (4140 and/or 90 mmHg) were enrolled in this prospective study. The inclusion criteria for entry was essentially hypertension with proteinuria (40.5/day) or hypertension with chronic renal parenchymal disease. The patients with moderate renal dysfunction (serum creatinine 43.0 mg/dl), severe hypertension (4180/ 120 mmHg), polycystic kidney disease, or diabetes mellitus were excluded from the study. The subjects included had either received no antihypertensive agents (n ¼ 19) or had been taking amlodipine (2.5-10 mg/day, n ¼ 29) or ACE inhibitors (trandolapril, 0.5-1.0 mg/day, n ¼ 2; lisinopril, 10-20 mg/day, n ¼ 2; enalapril, 5-10 mg/day, n ¼ 6) before entry into this study. There was no significant difference in sex, age, systolic/diastolic BP, aetiology of renal disease, or urinary protein excretion between the group not taking any antihypertensive agent and that on amlodipine or ACE inhibitor therapy ( Table 1 ). The patients taking other ARB (eg, losartan or valsartan) were excluded from this study. The patients had been instructed to restrict the intake of dietary protein (0.8 g/kg/day) and sodium (7 g/day) at least 3 months before their enrollment in this study. The study was approved by the Institutional Ethical Committee, and informed consent had been obtained from all subjects before starting the study.
Protocol
Twice at every month visit office BP was measured in the sedentary position. We followed all the American Heart Association Recommendations published in 1998, including the use of a 47 Â 13 cm 2 cuff and 24 Â 13 cm 2 bladder to avoid cuff hypertension. 12 The cuff was strictly positioned 2 cm above the antecubital crease to obtain a similarly levelled complete compression of the brachial artery.
After a 4-week control period, the patients with hypertension (4140/90 mmHg) were given CDS at a starting dose of 4 mg/day, and the dose was titrated to achieve BP below 140/90 mmHg up to a maximal dose of 12 mg/day. Total observation period of the study was 12 months. Serum levels of electrolytes, creatinine, and aldosterone and daily urinary protein excretion were measured every 3 months. Daily urinary protein excretion was determined by collecting 24-h urine samples, and urinary protein concentrations were determined by the pyrogallol red molybdate method.
Statistical analysis
Data are expressed as mean7s.e.m. Statistical analysis was performed with a two-way ANOVA or unpaired Student's t-test as appropriate. w 2 test was used for comparison of the number of male/female patients and the aetiology of renal disease between the monotherapy and the combination therapy group. P-values less than 0.05 were considered statistically significant.
Results
Overall effects of candesartan
BP was significantly decreased at 1 month (from 15571/9371 to 14471/8871 mmHg, Po0.01, n ¼ 58), and nearly maximal reductions in BP were Results are mean7s.e.m. Statistical analysis was performed with unpaired Student's t-test for comparison between two groups, except the number of male/female and the aetiology of renal disease, for which w 2 test was used.
Effect of candesartan plus amlodipine/ACE inhibitors on proteinuria K Homma et al achieved at 2 months (14071/8171 mmHg, Po0.01). Thereafter, the depressor action of CDS was sustained throughout the study. At the end of the protocol, a mean dose of CDS was 7.8 mg/day. Urinary protein excretion was significantly decreased at 3 months (from 1.9370.22 to 1.0270.12 g/day, Po0.01, n ¼ 58), and this beneficial effect persisted throughout the study period. At 12 months, CDS caused a 3774% reduction in proteinuria. Furthermore, the decrements in proteinuria observed at 3 months were the most marked in the group manifesting 420 mmHg reductions in systolic BP (À0.6770.12 g/day, n ¼ 10), when compared with other groups (o10 mmHg reduction, À0.4070.21 g/day, n ¼ 17; 10-20 mmHg reduction, À0.3270.11 g/day, n ¼ 31; Po0.05). The same tendency was observed at 12 months. Of note, the decrements in proteinuria were nearly the same in the group with o10 mmHg and that with 10-20 mmHg reductions in systolic BP (P40.5).
There was no change in serum creatinine levels throughout the 12-month study protocol (0 week, 1.170.1 mg/dl; 3 months, 1.470.2 mg/dl; 12 months, 1.470.3 mg/dl; n ¼ 58, P40.5). Serum potassium concentrations at the start of the study were 4.270.1 mEq/l (n ¼ 58), and CDS had no effect on serum potassium concentrations (P40.5). In patients with baseline serum creatinine concentration above 1.5 mg/dl, however, a significant increase in serum potassium levels was seen (from 4.370.1 to 4.770.1 mEq/l, Po0.05, n ¼ 16) although the maximal potassium levels did remain within normal ranges.
Plasma aldosterone levels before CDS treatment were 12579 pg/ml (n ¼ 58). At 3 months of CDS therapy, a significant decrease in aldosterone concentrations was observed (7979 pg/ml, Po0.05), and this change was sustained throughout the protocol period; a 3975% reduction in aldosterone concentration was noted at 12 months of treatment.
Comparison between CDS monotherapy and CDS plus amlodipine/ACE inhibitor combination therapy
Baseline characteristics in patients treated with the CDS monotherapy and CDS combination therapy (CDS plus amlodipine/ACE inhibitors) before entry are shown in Table 1 . No difference was noted between these two groups for any of the parameters.
When the effect of CDS on BP was compared in the absence or presence of amlodipine/ACE inhibitors, CDS exerted similar degrees of hypotensive action ( Figure 1) ; at 1 month, 871 mmHg reduction in systolic BP was observed with the CDS monotherapy (from 15473 to 14673 mmHg, Po0.05, n ¼ 19), and 971 mmHg reduction with the combination therapy with CDS plus amlodipine/ACE inhibitors (from 15372 to 14472 mmHg, Po0.05, n ¼ 39). These depressor actions persisted throughout the study. At 12 months, no difference in systolic BP was noted among these groups (CDS, 14073 mmHg; CDS þ amlodipine/ACE inhibitors, 13972 mmHg; P40.5). Similarly, diastolic BP manifested slight decreases, with nearly the same decrements in these two groups. Figure 2 illustrates the effect of CDS monotherapy and CDS plus other hypotensive agents on urinary protein excretion. To facilitate comparison of the effect on proteinuria between these groups, the same results are converted into the % changes from 0 month (ie, baseline), and depicted in the right panel of Figure 2 . In the CDS monotherapy group, urinary protein excretion was decreased by 4374% (from 1.7470.22 to 0.9770.16 g/day, Po0.01, n ¼ 19) at 3 months, and remained suppressed during the subsequent period. A greater antiproteinuric action was observed with the CDS add-on therapy. Thus, at 3 months, CDS add-on therapy caused a 5974% (from 2.1070.19 to 0.8670.28 g/day, n ¼ 39, Po0.01) decrease in proteinuria in the CDS plus amlodipine/ACE inhibitor group (Po0.01 vs CDS monotherapy). Furthermore, this beneficial action was sustained, with 5274% reductions observed with CDS plus amlodipine/ACE inhibitors therapy at 12 months.
The CDS treatment did not alter serum creatinine (CDS monotherapy, from 1.070.1 to 1.170.1 mg/dl, n ¼ 19; combination therapy, from 1.170.1 to 1.170.1 mg/dl, n ¼ 39) or potassium concentrations (CDS monotherapy, from 4.370.1 to 4.370.1 mg/dl; combination therapy, from 4.370.1 to 4.370.1 mEq/ l) in either group. Similarly, CDS had no effect on blood haemoglobin levels in the CDS monotherapy (from 15 
Discussion
In the present study, we have demonstrated that the CDS treatment, either as a monotherapy or as a combination therapy, is very potent in controlling BP in hypertension with renal disease. Furthermore, CDS elicits sustained proteinuria-sparing effect, 10, 11, 13 and would share the renoprotective action with ACE inhibitors, since the degree of proteinuria per se is acknowledged as a critical factor promoting the development of renal injury. 2 Of note, BP is established as an important determinant of the progression of renal injury. 4, 5 Indeed, the present study shows that a greater reduction in proteinuria was observed in the group with decrease in systolic BP 420 mmHg than that in the groups with less decrease in BP (ie, o20 mmHg). Nevertheless, a substantial reduction in proteinuria was also achieved in the group with only a modest decrease in systolic BP (o10 mmHg). Several lines of investigation demonstrate that ARB reduces the glomerular capillary pressure by dilating the efferent arteriole, 14, 15 and this decrease is expected to contribute in part to renal protection.
The role of the combination therapy in the treatment of renal injury merits comment. It has recently been demonstrated that the combination therapy with ramipril and felodipine caused a more pronounced improvement in the progression of renal damage than either of these agents alone. 16 The present study reveals further potentials for ARB in the treatment of hypertension with renal disease. Thus, in patients in which the treatment with amlodipine or ACE inhibitors alone failed to achieve the target BP, the add-on therapy with CDS produced a sufficient reduction in BP (Figure 1) . In this setting, urinary protein excretion was markedly reduced; the magnitude of the decrease was greater than that observed during the treatment with a CDS monotherapy (Figure 2 ). Since BP is obtained at the same levels in the CDS monotherapy and the combination therapy, a greater proteinuria-sparing effect of the combination therapy suggests an important role of the pre-existing antihypertensive agents as a determinant of antiproteinuric action of CDS. Although caveat is in order because of the nature of this study design (ie, a nonrandomised study), the current study would obviously facilitate the recognition of the important role of the combination therapy in the treatment of hypertension with chronic renal disease.
The precise mechanism for the exaggerated proteinuria-sparing action of CDS remains unclear. In the face of sustained systemic hypertension, the calcium antagonist may cause glomerular hypertension by dilating afferent arterioles, 17 and the subsequent efferent arteriolar dilation by the ARB add-on therapy could provoke a more substantial reduction in glomerular capillary pressure than that by the ARB monotherapy. Alternatively, Jinno et al Effect of candesartan plus amlodipine/ACE inhibitors on proteinuria K Homma et al action of the combination therapy of ARB and the calcium antagonist. Numerous investigators examine the effect of the combination treatment with ARB and ACE inhibitors in patients with chronic renal disease. Russo et al 10 demonstrated that a combination of losartan and enalapril produced a more marked reduction in proteinuria compared to either agent alone in patients with IgA nephropathy with normal renal function, and suggested a substantial advantage of the combination therapy. The combination therapy with CDS and ACE inhibitors has also been found to reduce protein excretion more successfully than either agent alone in type II diabetic nephropathy. 19, 20 These previous data along with our present findings suggest a more beneficial action of the combination therapy with ARB and ACE inhibitors than that of a monotherapy with either of the compounds in ameliorating proteinuria, and may be ascribed to more complete blockade of the angiotensin II action. 20 Alternatively, as shown in the present study, ARB may cause sustained suppression of plasma aldosterone levels, since the restoration of the aldosterone level is frequently observed during the long-term treatment with ACE inhibitors (ie, aldosterone breakthrough), 21 that may be associated with the development of renal injury. 22 This possibility warrants further investigations.
Although the combination therapy (ie, CDS plus amlodipine/ACE inhibitors) exerts greater antiproteinuric action than the CDS monotherapy, it remains undetermined whether either of these combination therapies is preferable in renal disease. In several clinical trials, including COOPERATE study 11 CALM study, 19 no significant increase in the incidence of hyperkalaemia has been reported during dual blockade of the renin-angiotensin system, compared with that subtending the ACE inhibitor monotherapy. In the present study, we find no significant effect on serum creatinine, potassium, or blood haemoglobin levels. However, the CDS plus ACE inhibitor group manifested a modest decrease in blood haemoglobin levels (from 14.970.4 to 13.870.4 g/dl, P ¼ 0.07, n ¼ 10), a finding consistent with that reported by Kuriyama et al 20 . Furthermore, when assessed in the subset of the group with baseline serum creatinine 41.5 mg/dl, serum potassium levels tended to rise in the CDS plus ACE inhibitor group (from 4.470.1 to 5.270.3 mEq/l, P ¼ 0.05, n ¼ 3), whereas no alteration was noted in the ARB plus amlodipine group (from 4.270.1 to 4.570.1 mEq/l, n ¼ 8). Although not statistically significant these changes should be taken into consideration when the combination therapy is introduced.
In conclusion, the present study demonstrates that during the treatment with amlodipine or ACE inhibitors, the CDS add-on therapy ameliorates proteinuria more markedly than the ARB monotherapy despite the same level of BP attained by the monotherapy and combination therapy. The equipotency of the combination therapy with ARB plus amlodipine and that with ARB plus ACE inhibitors suggests an important strategy for the treatment of hypertension with renal impairment.
